(Corrected at 9:25 am, January 25: An earlier version of the article did not contain sales figures in the correct currency for Rybelsus and Ozempic.)
The past year saw splendid sales of the one drug, whereas the other has left something to be desired.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.